Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06016023
Other study ID # RINDAPERIO2023
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 2023
Est. completion date October 15, 2024

Study information

Verified date September 2023
Source Postgraduate Institute of Dental Sciences Rohtak
Contact ADITI SANGWAN, MDS
Phone 9996002408
Email aditidalal86@yahoo.co.in
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Periodontal disease is a chronic progressive state of inflammation pertaining to supporting tissues of the dentition that culminates in loss of the affected teeth. Currently, diagnosis and monitoring of periodontal disease progression is accomplished by performing a full-mouth clinical and radiological examination which is time-consuming and also requires elaborate infrastructure and equipment, which are not always available. Limitations of the conventional diagnostic techniques necessitate the development of point-of-care testing (POCT) which could serve as a rapid, feasible and affordable screening tool for periodontal disease.MIP-1α is a cysteine-cysteine (C-C) chemokine that is secreted by a variety of cells like macrophages, fibroblasts, epithelial cells and endothelial cells. They principally serve to recruit leukocytes like monocytes, T lymphocytes, natural killer cells, dendritic cells and granulocytes to the site of inflammation. Hence, the current study has a two fold aim; first, to determine the feasibility of MIP-1α as a periodontal disease biomarker; and second, to correlate the value of MIP-1α obtained from oral rinse sample with the periodontal disease severity.


Description:

Periodontal disease is a chronic progressive state of inflammation pertaining to supporting tissues of the dentition that culminates in loss of the affected teeth. The term broadly covers both gingivitis (inflammation of the gingival connective tissue) and periodontitis (loss of supporting alveolar bone as a consequence of sustained inflammatory load on the supportive periodontal tissues). Currently, diagnosis and monitoring of periodontal disease progression is accomplished by performing a full-mouth clinical and radiological examination which is time-consuming and also requires elaborate infrastructure and equipment, which are not always available. These limitations of the conventional diagnostic techniques necessitate the development of point-of-care testing (POCT) which could serve as a rapid, feasible and affordable screening tool for periodontal disease. Of late, chemokines have become the subject of interest for potential application as biomarkers for periodontal screening. MIP-1α is a cysteine-cysteine (C-C) chemokine that is secreted by a variety of cells like macrophages, fibroblasts, epithelial cells and endothelial cells. They principally serve to recruit leukocytes like monocytes, T lymphocytes, natural killer cells, dendritic cells and granulocytes to the site of inflammation. The primary challenge faced by researchers in analysis of host derived oral biomarkers in any sample fluid is the establishment of normal level of various biomarkers. This problem arises as the biomarkers that are found at exaggerated levels in periodontal inflammation are also detected in oral fluids in healthy periodontium but at a much lower value. Hence, the current study has a two fold aim; first, to determine the feasibility of MIP-1α as a periodontal disease biomarker; and second, to correlate the value of MIP-1α obtained from oral rinse sample with the periodontal disease severity.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date October 15, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria: Presence of = 20 natural teeth - Ability and willingness to give written informed consent - Patients belonging to 4 groups -periodontally healthy, generalized gingivitis, generalized stage I/II periodontitis, generalized stage III/IV periodontitis Exclusion Criteria: - • Patients with chronic inflammatory disease such as nephrotic syndrome, chronic renal failure, significant cardiovascular disease, established type 1 or type 2 diabetes mellitus, or active cancer within the past 5 years - Smokers and alcoholics - Pregnant females - Presence of xerostomia - Patients with oral lesions or other contact sensitivity - Patients suffering from autoimmune diseases such as Sjogren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis - Patients with acute or chronic use of medications that cause oral dryness - Patients undergoing radiotherapy - Patients with Grade C periodontitis - Having received professional periodontal treatment within the previous 12 months - Having received antibiotic medication 3 months prior to study - Periapical pathology or other oral inflammatory conditions - Cognitive disability (interfering with ability to give samples)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
India Post Graduate Institute of Dental Sciences Rohtak Haryana

Sponsors (1)

Lead Sponsor Collaborator
Postgraduate Institute of Dental Sciences Rohtak

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of Macrophage Inflammatory Protein-1a (MIP-1a) level Evaluation of MIP-1a level in sample across 4 groups of systemically healthy individuals (periodontally healthy, generalized gingivitis, generalized stage I/II periodontitis, generalized stage III/IV periodontitis) 12-14 months
Primary To correlate the MIP-1a levels with clinical periodontal parameters To correlate the MIP-1a levels with clinical periodontal parameters (Gingival Index, Clinical Attachment Loss, Bleeding On Probing, Probing Pocket Depth) 12-14 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05568290 - Interleukin-38 Levels in Individuals With Periodontitis
Completed NCT04402996 - Meteorin-like Levels in Individuals With Periodontitis
Not yet recruiting NCT05497895 - The Assessment of Clinical Efficacy of Topical Application of 5% Thymoquinone Gel for Gingivitis Patients Early Phase 1
Completed NCT02552589 - Effect of Toothpaste on the Reduction of Plaque and Inflammation N/A
Completed NCT02884817 - Essential Oil+ELA, Plaque and Gingivitis Phase 4
Completed NCT02633345 - Effects on Tablets Containing Probiotic Candidate Strains N/A
Unknown status NCT01956656 - Efficacy Of Lotus Leaves In Management Of Plaque Induced Gingivitis N/A
Completed NCT02980497 - Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study N/A
Completed NCT02515929 - Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs Phase 4
Completed NCT02235532 - Effects of Aloe Vera Toothpaste on Periodontal Parameters N/A
Completed NCT02508987 - Obesity and Oxidative Stress in Patients With Different Periodontal Status N/A
Completed NCT01941797 - Experimental Peri-implant Mucositis in Humans N/A
Unknown status NCT01197105 - Evaluation Study of a Mouthwash Based on Schinus Terebinthifolius to Treat Gingivitis in Children Phase 1/Phase 2
Completed NCT01593540 - Clinical Examination of Metal Free Interdental Brushes Phase 4
Completed NCT01236963 - Essential Oils Mouth Rinse and Dental Floss: Efficacy on Interproximal Gingivitis and Dental Plaque Accumulation N/A
Completed NCT02102295 - Effects of Antioxidant Dentifrice on Gingivitis Phase 3
Completed NCT06140784 - A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices N/A
Completed NCT02937636 - To Investigate the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population N/A
Completed NCT06212908 - Assessment of Periodontal Therapy and Biofilm Management in Breast Cancer N/A
Completed NCT03641989 - Correlation Between Oral Health and Systemic Inflammation (COHESION) N/A